• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal

  • An Open, Single-Centre, Randomized, 6-way Crossover, Dose-Response Comparative Study of Esomeprazole 20, 40 and 80 mg and Pantoprazole 20, 40 and 80 mg regarding 24-hour Intragastric pH following 5 Days Repeated Oral Dose Administration in Patients with Symptoms of Gastroesophageal Reflux Disease

Disease
gastrointestinal diseases
Drug Name
Nexium
Generic Name
esomeprazole
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
I
Start Date
Feb 15, 2006
Study Name
D9612C00026
Study Id
D9612C00026
ClinicalTrials.gov ID
Not Applicable
Recruiting Status
Closed
Protocol Status
Not Available
Report
Jan 18, 1971
  • D9612C00026.pdf (135 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013